is the fda banning tirzepatide 🚨 Important Update on Compounded 🚨, As of March 19th, has officially banned compounded Tirzepatide formulations. We believe this a huge disservice to patients seeking affordable 🚨 FDA Moves to Permanently

58 Consequently, GLP-1 RAs are currently evidence-based treatments for common conditions that not only differentially affect persons with SMI-SUD but also contribute to the morbidity and mortality of these conditions

It can be prescribed to: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight and a weight-related health condition, such as high cholesterol, high blood pressure, type 2 diabetes, or sleep apnea Adults who have heart disease and either obesity or overweight Some people should avoid taking Wegovy

Should a patient become pregnant while using the solution, discontinuation is generally recommended until pregnancy and nursing have concluded

cardiometabolic markers

If yes, continue

Public sources such as the CDC, the National Institutes of Health, the FDA drug label and approval databases, and the World Health Organization help with prevalence trends, indication definitions, and major label changes over time